Retatrutide
Triple agonist research peptide (LY3437943).
Editor's picks.
A laboratory overview of retatrutide (LY3437943) — a triple agonist research peptide acting on the GLP-1, GIP and glucagon receptors.
6 min read →Product ComparisonsSide-by-side comparison of retatrutide and tirzepatide across receptor profile, research context and analytical considerations.
5 min read →2 guides
Background on retatrutide in the academic literature — receptor pharmacology, study context and analytical handling.
8 min read →Product ComparisonsHow retatrutide and semaglutide differ in receptor activity, compound class and laboratory research framing.
5 min read →Related products.
Compare research compounds.
Triple vs dual incretin agonist — receptor profile and research framing.
View comparison →Side by sideTriple agonist vs single GLP-1 — class, mechanism and lab context.
View comparison →Side by sideSelective GLP-1 agonist vs dual GIP/GLP-1 agonist — receptor pharmacology and evidence comparison.
View comparison →Frequently asked questions.
Is retatrutide approved for human use?
No. Retatrutide is supplied strictly for laboratory research and is not approved for human or veterinary administration.
Read: What is Retatrutide? →What receptors does retatrutide act on?
In published research it has been characterised as a triple agonist acting on the GLP-1, GIP and glucagon receptors.
Read: What is Retatrutide? →How should retatrutide be stored?
Lyophilised vials are stored at 2–8°C, protected from light. Once reconstituted with bacteriostatic water, store refrigerated and use within 30 days.
Read: What is Retatrutide? →Why is retatrutide of interest to researchers?
Its simultaneous activity at three incretin-related receptors makes it a useful tool compound for probing combined signalling pathways in metabolic research.
Read: Retatrutide Research Overview →